A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

NCT01080664 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

124

Enrollment

INDUSTRY

Sponsor class

Stopped Please see Purpose Statement below

Conditions

Haematological Malignancies

Interventions

DRUG: AS703569
DRUG: AS703569

Sponsor

EMD Serono